Showing 2821-2830 of 5018 results for "".
Comorbidities in Alopecia Areata
https://practicaldermatology.com/issues/july-2025/comorbidities-in-alopecia-areata/36507/Alopecia areata (AA) is a chronic, relapsing immune-mediated disorder that causes nonscarring hair loss that can significantly impact a patient’s quality of life.Study Examines Socioeconomic Status and HS Diagnosis
https://practicaldermatology.com/series/dermwire-tv/study-examines-socioeconomic-status-and-hs-diagnosis/35859/In this week's DermwireTV, a new study examines the association between socioeconomic status and HS diagnosis; a new meta-analysis highlights the therapeutic potential of simvastatin for vitiligo; and in our “Updates on Skin Cancer” feature, we hear about how to use gene expression profile testing fThe View from Under the Hood
https://practicaldermatology.com/issues/january-february-2025/the-view-from-under-the-hood/32967/As 2025 brings new approvals for treatments for hidradenitis suppurativa, chronic spontaneous urticaria, psoriatic arthritis, and several other diseases that need answers, this is a good time for us to remember that the most important approach to treatment starts with the right diagnosis.Comorbidities in Immune-mediated Skin Disorders: What’s Coming
https://practicaldermatology.com/issues/january-february-2025/comorbidities-in-immune-mediated-skin-disorders-whats-coming/32968/Comorbidities in immune-mediated skin disorders (IMSDs) occur frequently and have a significant impact on disease severity, treatment, prognosis, and quality of life.The Latest on Systemic Agents for Psoriasis: A Q&A With Jashin J. Wu, MD, FAAD
https://practicaldermatology.com/programs/practical-dermatology-focus-psoriasis/the-latest-on-systemic-agents-for-psoriasis/29073/The pharmacologic pipeline continues to produce strong options for systemic treatment of psoriasis. Practical Dermatology® spoke with Editorial Board member Jashin J. Wu, MD, FAAD, Founder and CEO of the Dermatology Research and Education Foundation, to discuss the latest treatment considerations wiDeveloping Core Outcome Sets: The Importance of Common Standards for Clinical Studies of Specific Diseases and Conditions
https://practicaldermatology.com/topics/feature/developing-core-outcome-sets-importance-common-standards-clinical-studies-specific-diseases-and-conditions/26654/Developing Core Outcome Sets: The Importance of Common Standards for Clinical Studies of Specific Diseases and ConditionsLead from Ahead (For a Change)
https://practicaldermatology.com/topics/practice-management/lead-from-ahead-for-a-change/23973/Structure: The Backbone of a Practice Transaction
https://practicaldermatology.com/topics/practice-management/structure-the-backbone-of-a-practice-transaction/23961/Access Is Everything
https://practicaldermatology.com/topics/practice-management/access-is-everything/23942/The Safe Step Act of 2023 seeks to rein in fail-first policies and protect patients.Close Up With Mikkel Østergaard, MD, PhD, DMSc
https://practicaldermatology.com/topics/close-up/close-up-with-mikkel-ostergaard-md-phd-dmsc/23941/